The Ministry of Public Health (MINSAP) reported on its website that this figure includes convalescents after more than two months of having the disease who received a single dose of the Soberana Plus vaccine, developed by the Finlay Vaccines Institute (IFV).
On January 11, 9,322,241 people had received a second dose of Soberana 02, also designed by the IFV, or Abdala, created by the Center for Genetic Engineering and Biotechnology (CIGB).
A third injection was given to 8,976,554 people.
The vaccination scheme was completed with two doses of Soberana 02 and one dose of Soberana Plus, or three doses of the Abdala vaccine for 9,745,230 Cubans, accounting for 87.1 percent of the country’s population, according to the report.
So far, 31,975,625 vaccine doses have been administered in Cuba.
On the other hand, the administration of the booster vaccine has so far benefited 3,172,790 individuals, as part of an accelerated strategy in view of the detection of the Omicron variant of the SARS-CoV-2 coronavirus in the national territory.
Of this total, 183,364 people participated in a clinical study and 2,989,426 lived in selected territories and were members of risk groups.